18 news items
Candel Reports Upbeat Data From Lung Cancer Study
CADL
KRYS
MRNS
24 May 24
survival data from a phase II study evaluating its lead investigational adenovirus immunotherapy candidate, CAN-2409 plus valacyclovir (prodrug
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
CADL
23 May 24
School of Medicine, University of Pennsylvania and Co-Principal Investigator of the clinical trial. Highlights
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
AZN
CADL
LTRN
23 May 24
).
Oncolytics will investigate the correlation between tumor responses and the increase of tumor-infiltrating lymphocytes (TILs) in the blood during
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
AZN
CADL
LTRN
23 May 24
).
Oncolytics will investigate the correlation between tumor responses and the increase of tumor-infiltrating lymphocytes (TILs) in the blood during
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
CADL
20 May 24
-2409, Candel's most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus
fn9di1pmiw6tvdm0c09ob0lq8lvwcdkw9t
ABVC
AMGN
CADL
15 May 24
the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for pancreatic cancer treatment. Thus, the intent
ae456k5i
ABVC
AMGN
CADL
15 May 24
the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for pancreatic cancer treatment. Thus, the intent
hx4rp4jspqfh5154x2r9xbx2ubjzuab21iin3o3
AZN
CADL
HALO
9 May 24
and primary investigator of the GOBLET trial. "My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging anal
ypxq5o5789ctxpo80xpa3fa803eh
AZN
CADL
HALO
9 May 24
and primary investigator of the GOBLET trial. "My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging
nbd waqwl19ekynymhle61q46v339yht1m73ww
AZN
CADL
HALO
9 May 24
Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial
5j2od0rz
AZN
CADL
HALO
9 May 24
Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial
wsyu3rmwp3sqf96gbosxjws oed
CADL
11 Apr 24
indication.About CAN-2409CAN-2409, Candel's most advanced multimodal biological immunotherapy candidate, is an investigational
w5txtuoaq0h40ax1ojsjnnm36ih
CADL
9 Apr 24
improve anti-tumor immunity. The presentation describes the development of an investigational TLS-inducing multimodal therapeutic using the enLIGHTEN
4rvpfnmbf6ld8e5w3somh7p1 ilgp61edcou9awpoua
CADL
5 Apr 24
after standard of care (SoC) treatment.
The investigators observed a nearly doubling of the expected median overall survival (mOS
omy89efoed tmkv4rxu77gx2
CADL
1 Apr 24
of CAN-3110 in recurrent high-grade glioma.
The investigators observed a nearly doubling of the expected median overall survival (mOS
dzf3q5x2buozs4z3a4hhmg86ymqwsu6kra7zvm7bc4u7qm3w
CADL
28 Mar 24
investigational viral multimodal immunotherapies, as compared to standard of care, in non-small cell lung cancer (CAN-2409), pancreatic cancer (CAN-2409
6xpwlzbjm6apthqeazajw7kvvie8b18cdjhl9uowzk13kb8bg4
CADL
15 Mar 24
of Nestin in cancer cells. CAN-3110 is being evaluated in a phase 1b investigator-sponsored
cmtanb7icjp2vpvimnvut1xb6mc fhvxog9xtrurmn2qz
CADL
5 Mar 24
in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candel's enLIGHTEN™ Discovery Platform
- Prev
- 1
- Next